GlaxoSmithKline Pharmaceuticals strengthened its ESG profile with a 3.3% cut in water use and Zero Liquid Discharge at the Nashik plant.

The respiratory portfolio expanded with Trelegy and Nucala auto-injectors, alongside a successful multi-specialty launch of the Shingrix vaccine.

Mental wellbeing programs and employee safety training were prioritized.

CSR efforts reached over 41,400 marginalized individuals.

Operational efficiency and patient-focused product delivery remain core, with no fines or penalties reported and high complaint resolution rates.